Summary:
NeoGenomics launched its PanTracer Family of genomic profiling tests and Paletrra, an AI-driven spatial proteomics platform, at the 2025 ASCO Annual Meeting to enhance precision oncology and support faster, data-driven cancer treatment decisions.
Key Takeaways:
- PanTracer Family offers comprehensive genomic insights for advanced solid tumors, including options for tissue and liquid biopsy samples.
- Paletrra provides AI-powered spatial proteomics analysis to better understand the tumor microenvironment and support therapeutic development.
- NeoGenomics aims to accelerate precision medicine by equipping clinicians and researchers with high-impact diagnostic tools.
NeoGenomics, Inc., a provider of oncology diagnostic solutions that enable precision medicine, debuted its PanTracer Family, a comprehensive suite of genomic profiling tests for advanced solid tumors, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The company will also unveiled Paletrra, its new AI-driven spatial proteomics platform designed to provide clear, actionable insights from tissue samples.
“The debut of the PanTracer Family and Paletrra represents a significant milestone for NeoGenomics and a step forward in precision oncology,” says Warren Stone, president & chief operating officer at NeoGenomics. “By equipping clinicians and drug developers with the tools to make faster, more informed decisions, we’re helping transform cancer care and accelerate innovation across the continuum of oncology diagnostics.”
The PanTracer Family is designed to provide oncologists with timely and actionable genomic insights, supporting treatment decisions for patients with advanced-stage solid tumors. The portfolio includes PanTracer Tissue for comprehensive profiling from Formalin-Fixed, Paraffin-Embedded tissue, PanTracer LBx for liquid biopsy applications where tissue is unavailable or insufficient, and PanTracer Tissue + HRD, which adds homologous recombination deficiency testing to enhance therapy stratification. These assays can be used independently or as complementary tools, allowing clinicians to tailor their approach based on patient-specific needs. It also ensures fast, reliable access to the data needed to explore targeted therapies or clinical trials.
Paletrra is an AI-powered spatial proteomics platform that transforms precious tissue into high-plex, image-based insights. Built for translational research teams, Paletrra combines deep pathology expertise with integrated multimodal analysis to decode the tumor microenvironment and validate mechanisms of action. Paletrra provides a scalable, high-touch solution that enables both large biopharma and emerging biotech companies to make more informed therapeutic decisions—helping teams see the biology more clearly, faster, and with confidence.
Featured Image: NeoGenomics debuted its PanTracer Family of genomic profiling tests at ASCO 2025. Image: NeoGenomics
